Differentiated Portfolio

We offer a differentiated portfolio spanning five key therapeutic areas: oncology & immunology, CNS, women's health, primary care & lifestyle, and nephrology. Leveraging strong licensing-in and license-out capabilities—particularly in oncology—we meet diverse global medical needs and continuously advance healthcare.

Generics

Brands

505(b)(2)

Biosimilars

NCEs

Generics

Affordable Care for All

Our generics portfolio encompasses oral oncology and key therapeutic areas including CNS, oncology and immunology, primary care and lifestyle, and nephrology. We deliver high‑quality medicines to global markets, backed by specialized expertise and a proven track record in complex generics.

Key milestones include the first‑to‑market Lenalidomide in Europe, Gefitinib launches in 20 European countries at patent expiry, and the first approval for generic Vinorelbine softgel capsules.

Brands

Enhancing Market Access

Through strategic partnerships, we acquire or in‑license tail‑end medicines and leverage our commercial channels and regional expertise to expand their reach. This approach increases treatment access for patients and strengthens our presence in key therapeutic areas.

Our in‑licensed brands include oncology and immunology such as Alimta®, primary care and lifestyle such as Cialis®, women’s health including Mercilon®, Aclasta® and Evista®, and nephrology such as Kalimate®, launched across global markets.

505(b)(2)

Accelerating Drug Development

We leverage the 505(b)(2) regulatory pathway to accelerate the development and commercialization of differentiated drug products, improving efficiency and optimizing resources.

Our portfolio covers oncology, CNS, primary care and lifestyle, women’s health, and nephrology, including the anti‑obesity drug Qsymia® in Korea, highlighting our presence in the obesity treatment market.

Biosimilars

Affordable Biologic Therapies

We are committed to broadening patient access to biologic therapies by developing and commercializing high‑quality biosimilars through strategic partnerships.

Our portfolio includes Alymsys® in oncology and immunology, Denosumab in women’s health, and Darbepoetin in nephrology. These products improve treatment accessibility, reduce cost burdens for patients and healthcare systems, and meet the highest standards of safety and efficacy.

NCEs

Advancing Novel Therapies

We are actively exploring new chemical entities (NCEs) across global markets as part of our strategy to diversify and strengthen our portfolio. These innovative, patented drugs provide novel treatment options designed to improve patient outcomes.

Our NCE pipeline focuses on critical therapeutic areas such as oncology and immunology, and women’s health, with key products including Zepzelca® and Alyssa®.

Differentiated Portfolio

Generics

Brands

505(b)(2)

Biosimilars

NCEs

Generics

Affordable Care for All

Brands

Enhancing Market Access

505(b)(2)

Accelerating Drug Development

Biosimilars

Affordable Biologic Therapies

NCEs

Advancing Novel Therapies

Contact Us